Karyopharm Therapeutics(KPTI) - 2022 Q4 - Earnings Call Presentation
Karyopharm Therapeutics(KPTI)2023-02-15 14:51Selinexor Can Inhibit Multiple Targets of the JAK Pathway, Enabling Independent Suppression of MF cells and Potentially Complementing the Function of JAKi's1,2,3,4,5 | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------------------------------------------------------------|-------|--------------------------------------------------------------------------|-------|-------| | MF is driven by upstream mutations JAK2, CALR MPL \nof or | | Par-4 | Additiona ...